Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCBT with Flu/Cy/TBI for Hematologic Diseases
NCT00309842Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2005
- Primary completion
- Jul 2019
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of umbilical cord blood in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML) and 7 more, sponsored by Masonic Cancer Center. Primary endpoint: Overall Survival at 1 year. Started Jul 2005; status: completed.
02
Drugs
umbilical cord blood
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelofibrosis (MF)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00309842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309842.